Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428044 · ClinicalTrials.gov registry record · Phase 2
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 10
- Study locations
NCT07428044: Recruiting Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07428044 is a Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07428044, a Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Primary Outcome
Determine the MPR rate to neoadjuvant T-DXd, as assessed by central pathologic review, in patients with resectable stage II-IIIB (T3-4N2) HER2-amplified or HER2-mutated NSCLC. MPR is defined as the presence of ≤10% residual viable tumor in the primary tumor bed after neoadjuvant chemotherap
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (10)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Michigan
- University of Michigan (Data Collection Only) - Ann Arbor
Minnesota
- Mayo Clinic (Data Collection Only) - Rochester
Quebec
- Centre Hospitalier de l'Université de Montreal (Data Collection Only) - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2027-02-13 |
| Phase | Phase 2 |
What NCT07428044 shows while recruiting
NCT07428044 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT07428044 lists 10 locations in 5 states (New York, New Jersey, Michigan).
Frequently Asked Questions
What is clinical trial NCT07428044 about?
NCT07428044 is a clinical study titled "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer". The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
What is the current status of trial NCT07428044?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-13. Estimated completion is 2027-02-13.
What conditions does trial NCT07428044 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB.
What interventions are being tested in trial NCT07428044?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07428044?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07428044 being conducted?
This trial has 10 study locations across Michigan, Minnesota, New Jersey, New York, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07428044's enrollment target sits among peer trials
14 432nd of 454 higher than 22 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy